Physician profile
Max Crouse
NPI 1548827124
$5,723.63
in general payments reported to CMS, 2019-2025
37 companies · $1,789 in 2025
The $1,789 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.01 · 2021: $25.27 · 2022: $256 · 2023: $1,760 · 2024: $1,871 · 2025: $1,789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,395 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,394.82 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,110.02 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $726.44 | 2022-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $554.22 | 2022-2025 | |
| Glaxosmithkline, LLC. | $500.37 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $463.40 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $434.30 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Exact Sciences Corporation | $335.65 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $128.75 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $122.38 | 2023-2025 | |
| Beta Bionics, INC. | $113.63 | 2024 | Ilet Bionic Pancreas |
| Inspire Medical Systems, INC. | $111.42 | 2023-2025 | Inspire |
| Abbott Laboratories | $104.16 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Dynavax Technologies Corporation | $99.67 | 2023-2025 | Heplisav-B |
| Sanofi-Aventis U.S. LLC | $84.92 | 2023-2025 | |
| Lundbeck LLC | $81.15 | 2022-2025 | Vyepti |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $74.43 | 2023-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $58.54 | 2022-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.24 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $50.37 | 2023 | Xarelto |
| Xeris Pharmaceuticals, INC. | $48.13 | 2023 | Gvoke Hypopen |
| Cequr Corporation | $46.52 | 2025 | Cequr Simplicity |
| Abiomed | $39.75 | 2024 | Impella |
| Idorsia Pharmaceuticals US INC | $33.88 | 2022-2023 | Quviviq |
| Nestle Healthcare Nutrition INC. | $33.55 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.48 | 2024-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $33.38 | 2022-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $33.31 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Optinose US, INC. | $26.05 | 2024 | |
| Si-Bone, INC. | $25.27 | 2021 | |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Teleflex LLC | $23.01 | 2019 | |
| Verrica Pharmaceuticals INC. | $22.72 | 2024 | Ycanth |
| Impel Pharmaceuticals INC. | $21.89 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.70 | 2022 | |
| Seqirus USA INC | $18.51 | 2025 | Flucelvax, Fluad |
| Axsome Therapeutics, INC. | $17.78 | 2025 | Symbravo |
| Eisai INC. | $15.64 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Crouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.